[PDF] Top 20 <p>Re-Evaluating the Use of IFN-β and Relapsing Multiple Sclerosis: Safety, Efficacy and Place in Therapy</p>
Has 10000 "<p>Re-Evaluating the Use of IFN-β and Relapsing Multiple Sclerosis: Safety, Efficacy and Place in Therapy</p>" found on our website. Below are the top 20 most common "<p>Re-Evaluating the Use of IFN-β and Relapsing Multiple Sclerosis: Safety, Efficacy and Place in Therapy</p>".
<p>Re-Evaluating the Use of IFN-β and Relapsing Multiple Sclerosis: Safety, Efficacy and Place in Therapy</p>
... to use the highly effective, infusion-based monoclonal antibody treatments such as natalizumab, rituximab, and ocrelizumab as fi rst- line treatments, and accordingly, fewer and fewer newly diagnosed patients are ... See full document
10
<p>Vedolizumab in the Treatment of Ulcerative Colitis: An Evidence-Based Review of Safety, Efficacy, and Place of Therapy</p>
... demonstrated, the time to assess the drug concentrations and the related therapeutic drug window for VDZ remains unde fi ned. As stated by Pouillon et al, prior to the recom- mendation of therapeutic monitoring of VDZ, ... See full document
14
Pharmacology and clinical efficacy of dimethyl fumarate (BG-12) for treatment of relapsing–remitting multiple sclerosis
... The safety profile of BG-12 is well known from its use in thousands of patients with psoriasis, and undoubtedly quali- fies the drug for long-term ...of evaluating the effect of symptomatic therapies ... See full document
11
Comparison of efficacy and safety of oral agents for the treatment of relapsing–remitting multiple sclerosis
... TOWER was the second randomized, multicentered, double- blind, Phase III study by Genzyme (a Sanofi company) that compared teriflunomide 7 and 14 mg with placebo for up to 48 weeks. The study included dosing regimens set ... See full document
15
<p>Clinical evaluation of dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis: efficacy, safety, patient experience and adherence</p>
... Assessing patient experiences by means of patient- reported outcomes (PROs) is valuable in substantiating the effectiveness of treatment. 46 MS is known to signi fi - cantly impact the quality of life of patients. 47 ... See full document
12
<p>Stereoelectroencephalography in epilepsy, cognitive neurophysiology, and psychiatric disease: safety, efficacy, and place in therapy</p>
... often place multiple electrode leads in the cortex adjacent to sulci and at their ...automated multiple trajectory planning integrated with the EpiNav system which can reduce planning time while ... See full document
16
Dimethyl fumarate in the management of multiple sclerosis: appropriate patient selection and special considerations
... for relapsing multiple ...the Efficacy and Safety of Oral Fumarate in Relapsing–Remitting MS [DEFINE] and Comparator and an Oral Fumarate in Relapsing-Remitting Multiple ... See full document
12
Disease modifying treatments and symptomatic drugs for cognitive impairment in multiple sclerosis: where do we stand?
... (Natalizumab Safety and Efficacy in Relapsing Remitting Multiple Sclerosis) and SENTINEL (Safety and Efficacy of Natalizumab in Combination with Inter- feron ... See full document
7
<p>Review Of The Safety, Efficacy And Tolerability Of Fingolimod In The Treatment Of Pediatric Patients With Relapsing-Remitting Forms Of Multiple Sclerosis (RRMS)</p>
... Pediatric-onset multiple sclerosis (POMS) is an immune-mediated, demyelinating, neurodegenerative disease that accounts for 3 – 5% of all multiple sclerosis (MS) ...trial evaluating the ... See full document
6
Clinical efficacy, safety, and tolerability of fingolimod for the treatment of relapsing-remitting multiple sclerosis
... of relapsing-remitting multiple sclerosis (MS), a chronic and potentially disabling neurological ...first-line therapy, or those with rapidly evolving ...its efficacy, safety, ... See full document
11
The heritage of glatiramer acetate and its use in multiple sclerosis
... Multiple sclerosis (MS) is a chronic and progressively debilitating disease of the central nervous ...The efficacy of glatiramer acetate 20 mg/mL once daily as first-line treatment in ... See full document
13
<p>Dimethyl Fumarate in the Treatment of Relapsing-Remitting Multiple Sclerosis: Patient Reported Outcomes and Perspectives</p>
... of relapsing forms of ...(DMF) therapy, one of the most frequently used fi rst- line therapies ...for relapsing MS (relapsing remitting [RRMS] and active secondary progressive ...afavorable ... See full document
12
Induction or aggravation of other immune-mediated disorders by disease-modifying therapy in treatment of multiple sclerosis
... Interferon beta (IFN-β) and glatiramer acetate (GA) are the primary therapeutic immunomodulatory agents that interfere with relapsing-remitting multiple sclerosis (RRMS), and the most ... See full document
8
A regional consensus recommendation on brain atrophy as an outcome measure in multiple sclerosis
... the Efficacy and Safety of Oral Fumarate in Relapsing – Remitting Multiple Sclerosis; DMTs: Disease Modifying Therapies; ECTRIMS: European Committee for Treatment and Research in ... See full document
9
Emerging oral immunomodulating agents – focus on teriflunomide for the treatment of multiple sclerosis
... adjunctive therapy with IFN- β were presented at the European Committee for Treat- ment and Research in Multiple Sclerosis (ECTRIMS) meet- ing in ...with relapsing MS already on a ... See full document
14
Nuclear factor erythroid 2 related factor 2 is a critical target for the treatment of glucocorticoid resistant lupus nephritis
... The efficacy of oral DMF in the treat- ment of relapsing–remitting multiple sclerosis (RRMS) has been proven in two phase III studies: DEFINE (Deter- mination of the Efficacy and ... See full document
12
The use of natalizumab for multiple sclerosis
... plus IFN beta-1a 30 µ g via intramuscular injection ...on IFN beta-1a therapy ...combination therapy was 0.38 compared with 0.82 for IFN beta-1a alone, a 54% ... See full document
12
Current and emerging treatments for relapsing multiple sclerosis in Argentinian patients: a review
... Multiple Sclerosis II [CARE-MS II]) were recently ...subcutaneous IFN beta-1a (44 mg three times per week) in patients with RRMS who had not received prior disease-modifying ...versus ... See full document
7
Understanding and meeting injection device needs in multiple sclerosis: a survey of patient attitudes and practices
... device offers a number of innovative features designed to improve the convenience and comfort of subcutaneous IFN beta-1a administration. Patients using this device have the facility to improve injection ... See full document
8
The role of glatiramer acetate in the early treatment of multiple sclerosis
... was re-introduced into the market in 2006 after review of available scientific ...the re-introduction, a number of progressive multifocal leuko- encephalopathy (PML) cases have occurred (currently about ... See full document
8
Related subjects